Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2434MR)

This product GTTS-WQ2434MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, AMG 145(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ2434MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2851MR IVTScrip™ mRNA-Anti-ICOS, AMG-570(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-570
GTTS-WQ15899MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ13259MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06252616
GTTS-WQ10186MR IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LC1004-002
GTTS-WQ10283MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ4674MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-986089
GTTS-WQ14898MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ4223MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW